Safety and efficacy data on the investigational subcutaneous formulation of ORENCIA in adults with moderate to severe rheumatoid arthritis to be presented at the American College of Rheumatology ...

Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With ...

Dec. 29, 2005 — The U.S. Food and Drug Administration (FDA) has approved abatacept injection for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an ...

BARCELONA, Spain — Treatment with abatacept delays the onset of rheumatoid arthritis (RA) in patients at high risk of developing the disease, according to data presented at the European Alliance of ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Philip Day loved playing soccer so much that the 35-year-old software engineer founded a website -- FootballMatcher.com -- to help people connect for pickup games. The fun went on pause when Day ...

(NAPSI)ORENCIA (abatacept) is the first and only biologic for the treatment of adults with moderate to severe rheumatoid arthritis (RA) available in both self-injectable (under the skin) and ...

The FINANCIAL — Bristol-Myers Squibb Company announced on July 6 the U.S. Food and Drug Administration (FDA) has approved ORENCIA for the treatment of adults with active Psoriatic Arthritis (PsA), a ...

PRINCETON, N.J. — The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for injection under the skin to treat rheumatoid arthritis, Bristol said Friday. The New York-based ...